Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lot-to-lot consistency study of a 13-valent pneumococcal conjugate vaccine in children
ChiCTR2200059295Phase 4Not yet recruiting
- Sponsor
- Guangxi Center for Disease Control and Prevention
- Start
- May 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of 13-valent pneumococcal polysaccharide conjugate vaccine in pneumococcal disease (3 arms), sponsored by Guangxi Center for Disease Control and Prevention. Primary endpoint: Serum IgG antibody concentration of 13 pneumococcal serotypes. Planned start May 2022; status: not yet recruiting.
02
Drugs
13-valent pneumococcal polysaccharide conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on ChiCTR2200059295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059295.